Registration, Students and Bursaries

Registration is open, and discounted rates are offered to RSC and SCI student members. The RSC and SCI are also offering some student bursaries. Registration fees include:

– gratis coach transport between Verona city centre and the Evotec campus at the start and end of each day
– dinner on Wednesday evening at the Ristorante Trisapori (formerly Scaligero)
– vineyard visit and dinner on Thursday evening at Rocca Sveva.

Standard registration fees, for payment by 5th September:

£600 Member of the RSC or SCI
£800 Non-member
£250 Student member, unemployed member, retired member
£350 Student non-member, unemployed non-member, retired non-member

Venue, Travel and Accommodation

Venue: Evotec Campus Levi-Montalcini, Verona, Italy
Travel: Detailed travel information may be found on the website.
Accommodation: Verona Booking is offering a hotel booking service.

Sponsors

We are grateful to Evotec for their generous support of this event.Additional sponsors would be welcomed.

evotec
VERTEX THE SCIENCE of POSSIBILITY
ucb Inspired by patients. Driven by science.
sosei HEPTARES
sb drug discovery
charles river
Pharmacelera

Organising Committee

Daniele Andreotti, Evotec, IT
Adrian Hall (co-chairman), UCB, BE
Duncan Hay (treasurer), Vertex, UK
Caroline Low (co-chairman), Isomorphic Laboratories, UK
Nigel Swain, Sosei Heptares, UK

Exhibitor Opportunities

Please see our website for information about exhibitor opportunities.

Twitter #GPCRs22

Secretariat Contact

For further information, please contact the event secretariat: Maggi Churchouse, maggi.churchouse@rscbmcs.org

Website: https://www.rscbmcs.org
Also www.rsc.org/bmcs and www.soci.org/events

Second announcement and call for posters



8th RSC / SCI Symposium on GPCRs in Medicinal Chemistry

Wednesday-Friday, 5th-7th October 2022

Evotec Campus Levi-Montalcini Verona, Italy

Organised by:
RSC Biological and Medicinal Chemistry Sector and SCI Fine Chemicals Group

RSC INTEREST GROUP BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR

SCI

Synopsis

The key role of G protein-coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to be holding this 8th meeting in the series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.

Features of the Meeting

- Case studies in GPCR drug discovery and development
- Structural biology advances and impact on drug design
- Showcasing multiple modalities and drug discovery approaches to modulating GPCRs

Also: poster session - trade exhibition opportunities - two evening dinners and vineyard visit - accommodation agency booking service.

Call for Posters

Abstracts are invited for poster presentations. Applicants have the opportunity to provide a short flash oral presentation. The closing date is 11th August, and several prizes will be awarded. The call for oral abstracts closed on 31st March.

Programme Timings

To assist you with your travel plans, expected start and finish times are:
Day 1 08.30 Registration opens
Day 1 09.20 Technical programme starts
Day 3 15.00 Close of symposium

Confirmed Speakers

Discovery of VU6028418: a highly selective and orally bioavailable M4 muscarinic acetylcholine receptor antagonist
Aaron Bender, Vanderbilt University, US

Discovery of the clinical candidate ACT-777991, a potent CXCR3 antagonist with therapeutic potential in autoimmune diseases
Eva Caroff, Idorsia, CH

Understanding allostery at GPCRs
Keynote: Arthur Christopoulos, Monash University, AU

AlphaFold and GPCRs (provisional title)
Miles Congreve and Caroline Low, Isomorphic Laboratories, UK

Impact of GPCR structure-based drug discovery on identification and optimisation of allosteric modulators that bind at the receptor-membrane interface
Anna Cooper, Sosei Heptares, UK

The discovery of CFTX-1554 as an inhibitor of the angiotensin II type 2 receptor, a clinically validated target for the treatment of neuropathic pain
Ann De Blieck, Confo Therapeutics, BE

Achieving fine control of GPCR function via learning and simulation of 3D structure
Keynote: Ron Dror, Stanford University, US (virtual)

Confirmed Speakers (continued)

Structure-based drug discovery across the medicinal chemical GPCRome
Chris de Graaf, Sosei Heptares, UK

The resolution revolution:GPCR structure-based drug design in 20:20 vision (in 2022)
James Errey, Evotec, UK

Identification of H4R antagonist HTL0032547 as a potential therapy for atopic dermatitis
Charlotte Fieldhouse, Sosei Heptares, UK

Roadmap and resource for GPCR biased signalling
Keynote: David Gloriam, University of Copenhagen, DK (virtual)

Discovery of AZD5462, an oral agonist of the Relaxin family peptide receptor 1 (RXFP1) for the treatment of cardiorenal disease
Kenneth Granberg, AstraZeneca, SE

Discovery of potent and selective S1P2 receptor antagonists for treatment of idiopathic pulmonary fibrosis
Bertrand Heckmann, Galapagos, FR

GPCR-based drug design with fragment molecular orbital method
Alexander Heifetz, Evotec, UK

Targeting chemokine receptor CCR2 - from insurmountable antagonists to affinity-based probes
Laura Heitman, University of Leiden, NL

Discovery of MK-4710: a potent, selective, and bioavailable M4 positive allosteric modulator
Michael Lo, MSD, US

Salipro DirectMX® enables discovery of novel therapeutics against GPCRs
Robin Löving, Salipro, SE

Structure-guided GPCR drug discovery
Keynote: Bryan Roth, Eshelman School of Pharmacy, University of North Carolina, USA

How to leverage new AI technologies alongside traditional HTS to better validate hit compounds for GPCRs
Carleton Sage, Eurofins Discovery, US

Discovery of Pecavaptan: a novel dual acting vasopressin V1a/V2 receptor antagonist for the treatment of worsening chronic heart failure
Carsten Schmeck, Bayer, DE

Discovery of FPR2 agonists for treatment of heart failure
Nicholas Wurtz, Bristol-Myers Squibb, US

Website: https://www.rscbmcs.org
Also www.rsc.org/bmcs and www.soci.org/events